Ultravist shortage — US supply status & alternatives

Ultravist

—

🇦🇺 AUST R 15681 · Bayer Australia Ltd

In supply · Australia

In supply · 🇦🇺 Australia · short in🇺🇸 US🇨🇭 CH

In supply in Australia

Reading today’s signals…

✓ Can I substitute?

In supply

no shortage substitution needed

⇄ Best alternative

None listed

refer to prescriber

◷ Expected back

No estimate

No estimate provided

Product attributes reference data we hold

Active ingredient (INN)	Ultravist
Therapeutic category	Auto-created by Agencia Española de Medicamentos — Problemas de Suministro scraper
Controlled substance	No

Registrations on file	15

Patient information leaflet (PIL)	Not on file

Summary of product characteristics (SPC)	Not on file

Trade price 🇦🇺 Australia · awaiting price ingest

🇦🇺 AU

Ex-manufacturer

—

Dispensed (DPMQ)

—

Pack

—

Not yet captured for Australia

Official pricing isn’t on file for this market yet. PBS (Australia), NHS Drug Tariff (United Kingdom) and CMS NADAC (United States) feeds are prioritised; this panel populates automatically once the data lands.

Substitution pathways 🇦🇺 Australia · TGA

—

No substitution instrument in force

Dispense per normal rules, or refer to the prescriber. No active SSSI/S19A instrument detected for this medicine.

How long have past shortages lasted? from 1 resolved event

◷

~0 month

Historical pattern from resolved shortage records — not a prediction of this event.

Shortage status by regulator official notices

🇺🇸

United States

FDA MedWatch · 1mo ago

Critical

🇨🇭

Switzerland

Swissmedic · 1d ago

Medium

🇪🇸

Spain

AEMPS · 3mo ago

Resolved

Verified timeline regulator events

🇨🇭 5 July 2026

medium reported

🇨🇭 4 July 2026

medium reported

🇨🇭 1 July 2026

medium reported

🇨🇭 28 June 2026

medium reported

🇨🇭 27 June 2026

medium reported

🇨🇭 26 June 2026

medium reported

Sources official regulators

🇨🇭

Swissmedic

verified 1d ago

verify ↗

🇺🇸

FDA-FE

verified 2d ago

verify ↗

🇺🇸

FDA MedWatch

verified 1mo ago

verify ↗

🇪🇸

AEMPS

verified 3mo ago

verify ↗

Registration recordmarketing-authorisation holders

Registrations & marketing-authorisation holders15 registrations · 3 MA holders

Product	Strength	Form	Market	MA holder	Status
ULTRAVIST 370 iopromide 38.443g/50mL injection bottle	38.443g	—	🇦🇺 AU	Bayer Australia Ltd	Active
ULTRAVIST 240 iopromide 24.936g/50mL injection bottle	24.936g	—	🇦🇺 AU	Bayer Australia Ltd	Active
ULTRAVIST 300 iopromide 31.17g/50mL injection bottle	31.17g	—	🇦🇺 AU	Bayer Australia Ltd	Active
ULTRAVIST 370 iopromide 384.5 g/500 mL solution for injection bottle	384.5 g	—	🇦🇺 AU	Bayer Australia Ltd	Active
ULTRAVIST 300 iopromide 12.468g/20mL injection vial	12.468g	—	🇦🇺 AU	Bayer Australia Ltd	Active
ULTRAVIST 370 iopromide 76.88g/100mL injection bottle	76.88g	—	🇦🇺 AU	Bayer Australia Ltd	Active
ULTRAVIST 370 iopromide 153.77g/200mL injection bottle	153.77g	—	🇦🇺 AU	Bayer Australia Ltd	Active
ULTRAVIST 150 iopromide 62.34g/200mL injection bottle	62.34g	—	🇦🇺 AU	Bayer Australia Ltd	Active
ULTRAVIST 300 iopromide 62.34g/100mL injection bottle	62.34g	—	🇦🇺 AU	Bayer Australia Ltd	Active
Ultravist-	49.872g	—	🇦🇺 AU	Bayer Australia Ltd	Active
Ultravist	300mg/mL	injection	🇺🇸 US	Bayer HealthCare Pharmaceuticals Inc.	Active
Ultravist	370mg/mL	injection	🇺🇸 US	Bayer HealthCare Pharmaceuticals Inc.	Active
Ultravist 300	—	solution	🇨🇦 CA	BAYER INC	Active
Ultravist 370	—	solution	🇨🇦 CA	BAYER INC	Active
Ultravist 240	—	solution	🇨🇦 CA	BAYER INC	Active

Mederti Drug Report

Generated 7 July 2026 · Australia market · 4 regulatory sources

For health-professional reference only. Mederti aggregates shortage and substitution information from official regulatory sources. It is not clinical advice and data may be incomplete or delayed. Confirm any substitution or supply decision against the primary regulator source, the prescriber, and current clinical references (e.g. AMH) before acting. Terms.